Adaptimmune Therapeutics PLC · OTC:ADAPY

Adaptimmune Therapeutics — Jefferies Autumn Global Healthcare Conference 2015

42 slides from Adaptimmune Therapeutics's conference presentation, Nov 18, 2015

  1. Slide 1: Disclaimer

    Slide 1: Disclaimer

    Disclaimer This presentation contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “believe,” “may”, “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and o

  2. Slide 2: Investment Highlights

    Slide 2: Investment Highlights

    Investment Highlights Focused on affinity enhanced T-cell therapies for autologous T-cell therapeutics to treat cancer Lead clinical candidate targeting NY-ESO : SITC 2015 data Synovial sarcoma – In patients receiving target dose of 1x109 cells: 60% RR; 90% remain alive and on long-term follow up Mu

  3. Slide 3: TCR Platform built up over 16 years

    Slide 3: TCR Platform built up over 16 years

    TCR Platform built up over 16 years 1999-2006 Avidex formed on basis of TCR technology from Oxford University Acquired by Medigene (2006) 2008 Adaptimmune formed as a virtual company with UPenn collaboration 2011-2014 Adaptimmune establishes R&D infrastructure and delivers promising clinical data 20

  4. Slide 4: Experienced Management Team and Board

    Slide 4: Experienced Management Team and Board

    Experienced Management Team and Board Executive Management Name: Title: Experience: James Noble, MA, FCA CEO & Co-Founder Helen Tayton-Martin, PhD MBA COO & Co-Founder Adrian Rawcliffe CFO Rafael Amado, MD CMO Gwen Binder-Scholl, PhD EVP, Adaptimmune LLC Board of Directors Name: Affiliation: Experie

  5. Slide 5: TCRs recognize intracellular cancer antigens

    Slide 5: TCRs recognize intracellular cancer antigens

    TCRs recognize intracellular cancer antigens The TCR is the natural mechanism for T-cells to distinguish a diseased cell from a healthy cell All proteins, including intracellular ones, are processed and presented as HLA-peptide complexes which are recognized by TCRs Many cancer targets are intracell

  6. Slide 6: ADAP Pipeline: Next Steps with NY-ESO

    Slide 6: ADAP Pipeline: Next Steps with NY-ESO

    Indication Research Pre-IND Phase 1/2 GSK option to license ADAP Pipeline: Next Steps with NY-ESO Cohort 1: High NY-ESO expression, 12 patients Esophageal Synovial Sarcoma Cohort 2: Low NY-ESO expression, 10 patients Cohort 3: Removal of fludarabine, 10 patients Cohort 1: Autologous SCT, 25 patients

  7. Slide 7: ADAP Pipeline: Next Steps, Wholly-owned Targets

    Slide 7: ADAP Pipeline: Next Steps, Wholly-owned Targets

    MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 ADAP Pipeline: Next Steps Wholly-owned ADAP Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors NIH RAC approval received Hepatocellular cancer Synovial Sarcoma 12 undisclosed cancer targets AFP TCR Research programs Adapt

  8. Slide 8: Platform and Differentiation

    Slide 8: Platform and Differentiation

    Platform and Differentiation

  9. Slide 9: Finding the Right Targets

    Slide 9: Finding the Right Targets

    Finding the Right Targets Tumour cell Only low risk targets selected for TCR programs Over thirty validated targets and growing Engineered TCRs Safety Testing Robust Manufacturing Validated Targets Mass spectrometry Confirms surface expression and expression on tumor cells (i.e. not normal tissue) I

  10. Slide 10: NY-ESO expression in Normal Tissues

    Slide 10: NY-ESO expression in Normal Tissues

    NY-ESO 1 expression in Normal Tissues Expression is low/absent in most adult non-reproductive tissues Minimum NYESO1-TCR Activity Threshold* Normal Tissue Threshold** * = Level of expression of antigen required to be recognized by that specific TCR ** = Highest level of expression of antigen in non-

  11. Slide 11: MAGE-A10 expression in Normal Tissues

    Slide 11: MAGE-A10 expression in Normal Tissues

    MAGE-A10 expression in Normal Tissues Expression is low/absent in most adult non-reproductive tissues Normal Tissue Threshold** Minimum MAGEA10-TCR Activity Threshold* * = Level of expression of antigen required to be recognized by that specific TCR ** = Highest level of expression of antigen in non

  12. Slide 12: AFP expression in Normal Tissues

    Slide 12: AFP expression in Normal Tissues

    AFP expression in Normal Tissues Expression is low/absent in most adult non-reproductive tissues except the liver Minimum AFP-TCR Activity Threshold* Normal Tissue Threshold** * = Level of expression of antigen required to be recognized by that specific TCR ** = Highest level of expression of antige

  13. Slide 13: Natural Cancer Targeting TCRs Have Very Low Natural Affinity

    Slide 13: Natural Cancer Targeting TCRs Have Very Low Natural Affinity

    Natural Cancer Targeting TCRs Have Very Low Natural Affinity Aleksic, M. et al. (2012). Eur J Immunol 10.1002/eji.201242606 Strong Weak Antigen recognition Virus TCRs Naturally-occurring Cancer TCRs Viral TCRs have higher affinity than cancer TCRs and give better immune responses

  14. Slide 14: Sensitivity of natural T cells vs TCR Engineered cells to cancer

    Slide 14: Sensitivity of natural T cells vs TCR Engineered cells to cancer

    Sensitivity of natural T cells vs TCR Engineered cells to cancer Engineered TCR T cell activity Normal T cell reactivity No. of antigens per cell 1 10 20 50 100 500 - max activation - no activation - max activation - no activation Minority of T-cells mount anti-tumour response Majority of T-cells mo

  15. Slide 15: Achieving higher Affinity

    Slide 15: Achieving higher Affinity

    Achieving higher Affinity Safety Testing Robust Manufacturing Validated Targets Engineered TCRs 1mM 100mM 10mM 1mM Individual TCRs in test panel Natural T cell Response – natural affinity TCR Adaptimmune engineered TCR T cell response Increasing TCR affinity Soluble TCRs Phage Display Multiple Panel

  16. Slide 16: Proprietary platform enables engineering for maximum potency and specificity

    Slide 16: Proprietary platform enables engineering for maximum potency and specificity

    Proprietary platform enables engineering for maximum potency and specificity #1 20.1uM #2 11uM #3 10.6uM #4 8.0uM #5 4.55uM #6 4.2uM #7 1.5uM Natural Affinity 754uM Engineered TCR variants KD Tumour Cell1 (HLA-A2+, Ag+) Tumour Cell 2 (HLA-A2-, Ag+) Normal Cell 1 (HLA-A2+, Ag-) Right HLA, Right Antig

  17. Slide 17: Proprietary platform enables engineering for potency and specificity

    Slide 17: Proprietary platform enables engineering for potency and specificity

    Proprietary platform enables engineering for potency and specificity T cells without ADT TCR vs A375 melanoma (MAGE-A10 positive) T cells with MAGE-A10 ADT TCR vs A375 melanoma (MAGE-A10 positive) MAGE-A10 TCR T cell killing of 3D micro-tissues

  18. Slide 18: Proprietary Safety Testing: 3D primary cultures and iCells

    Slide 18: Proprietary Safety Testing: 3D primary cultures and iCells

    3D primary cultures and iCells Normal Primary Cell Screen Molecular Analysis Human Cell Testing Whole Blood Assay Allo-reactivity Screen “Core motif” identification Core motif genome search X-scan peptide mapping Redefined completely following two deaths on MAGE A3 study in 2011/12* *Linette et al,

  19. Slide 19: Alanine Scanning – Molecular Recognition - MAGE-A3

    Slide 19: Alanine Scanning – Molecular Recognition - MAGE-A3

    Alanine Scanning – Molecular Recognition - MAGE-A3 MAGE-A3 Peptide: EVDPIGHLY Alanine Scan: TCR Binding Critical amino Core motif acids for TCR recognition AVDPIGHLY X E E EADPIGHLY X EVAPIGHLY X D D EVDAIGHLY X P P EVDPAGHLY X I I EVDPIAHLY X EVDPIGALY X EVDPIGHAY X EVDPIGHLA X Y Y p1 p2 p3 p4 p5 p

  20. Slide 20: Core Motif Genome BLAST search identified Titin

    Slide 20: Core Motif Genome BLAST search identified Titin

    Core Motif Genome “BLAST” search identified Titin EXDPIXXXY Protein EKDPISDSY Clostridium novyi ELDPIYRKY Clostridium perfringens EKDPIKENY Clostridium difficile ENDPIINCY Clostridium perfringens EKDPIDTSY Clostridium tetani EQDPIYRKY Deinococcus radiodurans EGDPILWWY Desulfotalea psychrophila EIDPI

  21. Slide 21: Proprietary Process for Manufacturing

    Slide 21: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Leukapheresis Prepare patient with lymphodepletion Collection Infusion Natural T-cells isolated from patients Genes encoding enhanced TCR delivered to patient’s natural T-cells Lentiviral vector Enhanced T-cells expanded Exclusive license to DynaBeads® CD3/CD28

  22. Slide 22: Proprietary Process for Manufacturing

    Slide 22: Proprietary Process for Manufacturing

    Proprietary Process for Manufacturing Validated Targets | sp | Engineered TCRs | > | Safety Testing |» | Robust Manufacturing Leukapheresis Natural T-cells isolated from patients Genes encoding Engineered TCR enhanced TCR — delivered to patient's © Erne: ODO natural T-cells Vein to vein in 17 to 24

  23. Slide 23: ADAP Phase I/II Study in Synovial Sarcoma

    Slide 23: ADAP Phase I/II Study in Synovial Sarcoma

    ADAP Phase I/II Study in Synovial Sarcoma Generally incurable; 75% to 80% of patients do not survive past two to three years First line therapy: radiotherapy and chemotherapy, surgical resection where possible Study Design: Multicenter pilot study in 12 patients, objectives: Determine the response r

  24. Slide 24: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Slide 24: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence 60% response rate in the 10 patients who received target cell dose (at least 1x109 NY-ESO-1C259T cells) 50% overall response rate (6/12) in patients receiving any dose of cells 75% (9/12) of all patients - and 90% (9/10) patien

  25. Slide 25: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Slide 25: Synovial Sarcoma: Encouraging Response Rate, Tolerability and Persistence

    Synovial Sarcoma Encouraging Response Rate, Tolerability and Persistence Generally well tolerated; indicative of a favorable risk:benefit profile The majority of adverse events occur within the first 2 weeks following cell infusion and resolve within 30 days. Evidence of pseudo-progression and gradu

  26. Slide 26: Radiographic Pseudoprogression and Response of Lung Metastases

    Slide 26: Radiographic Pseudoprogression and Response of Lung Metastases

    ADAP Phase I/II Study in Synovial Sarcoma Radiographic Pseudoprogression and Response of Lung Metastases Baseline: Bilateral Miliary Metastatic disease Day +2: Pseudoprogression due to Immune Infilration Day +101: Complete Response Patient 201 NY-ESO C-Reactive Protein AACR April 2015

  27. Slide 27: Partial Response Followed by Tumor Resection in Sarcoma

    Slide 27: Partial Response Followed by Tumor Resection in Sarcoma

    NY-ESO TCR T cells administered ADAP Phase I/II Study in Synovial Sarcoma Partial Response Followed by Tumor Resection in Sarcoma One month post NY-ESO TCR T cells Two months post NY-ESO T cells Source: Merchant, CTOS, 2014 ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-

  28. Slide 28: NY-ESO TCR T cells administered

    Slide 28: NY-ESO TCR T cells administered

    NY-ESO TCR T ‘One month ‘Two months cells post NY-ESO post NY-ESO T administered TCR T cells cells * ~ 70% reduction in lesion size at 2 months after administration of NY-ESO T-cells * The lesion was then deemed capable of resection

  29. Slide 29: ADAP Phase I/II Study in Multiple Myeloma Study Design

    Slide 29: ADAP Phase I/II Study in Multiple Myeloma Study Design

    ADAP Phase I/II Study in Multiple Myeloma Study Design US prevalence: 77,600 cases - approximately 27,000 new cases expected in 2015 Average five-year survival rates are estimated to be less than 45 percent Study Design: All enrolled patients (n=25) had symptomatic myeloma with active disease High r

  30. Slide 30: Multiple Myeloma: Compelling Response Rate Compared to Published Literature

    Slide 30: Multiple Myeloma: Compelling Response Rate Compared to Published Literature

    ADAP Phase I/II Study in Multiple Myeloma Compelling Response Rate Compared to Published Literature Two year overall survival (OS) and progression free survival (PFS) as of November 2015 16/25 patients remain alive; 8/25 remain in remission Median PFS = 19.1 months Median OS = 32.1 months Response r

  31. Slide 31: Multiple Myeloma: Encouraging Tolerability and Persistence

    Slide 31: Multiple Myeloma: Encouraging Tolerability and Persistence

    ADAP Phase I/II Study in Multiple Myeloma Encouraging Tolerability and Persistence Generally well tolerated; indicative of a favorable risk:benefit profile All SAEs possibly related to the NY-ESO T-cells resolved No clinically apparent cytokine release syndrome despite high IL-6 levels CAR-Ts have b

  32. Slide 32: MAGE-A10 Proprietary target

    Slide 32: MAGE-A10 Proprietary target

    MAGE-A10 Proprietary target

  33. Slide 33: MAGE-A10 – A multi-cancer target

    Slide 33: MAGE-A10 – A multi-cancer target

    MAGE A10 expression from cancer genome atlas (TCGA) breast bladder lung head & neck melanoma ovarian NIH RAC March 2015 MAGE-A10 – A multi-cancer target MAGE A10 expression is absent/low in most adult non-reproductive tissue tissues

  34. Slide 34: IND for MAGE-A10 TCR therapeutic filed

    Slide 34: IND for MAGE-A10 TCR therapeutic filed

    IND for MAGE-A10 TCR therapeutic filed Preclinical testing complete NIH RAC approval obtained: March 10, 2015 IND approved: announced July 2, 2015 Initial trial in NSCLC expected to open in 2015 Basket study anticipated in 2016 in multiple cancers potentially including bladder, head and neck, breast

  35. Slide 35: ADAP Pipeline: Next Steps, Wholly-owned Targets

    Slide 35: ADAP Pipeline: Next Steps, Wholly-owned Targets

    MAGE-A10 TCR Indication Research Pre-IND Phase 1/2 ADAP Pipeline: Next Steps Wholly-owned ADAP Targets IND open Non-small cell lung cancer (NSCLC) Basket study: Solid tumors NIH RAC approval received Hepatocellular cancer Synovial Sarcoma 12 undisclosed cancer targets AFP TCR Research programs Adapt

  36. Slide 36: ADAP Pipeline: Next Steps, Wholly-owned Targets

    Slide 36: ADAP Pipeline: Next Steps, Wholly-owned Targets

    ADAP Pipeline: Next Steps Wholly-owned ADAP Targets Nae SUR Ce Me Non-small cell lung cancer (NSCLC) IND open Enrollment shortly Basket study: Solid tumors > Enrollment in 2016 Generation 2 L IND 2017 GRC ME Hepatocellular cancer NIH RAC approval received IND planned 1H 2106 Research programs Resear

  37. Slide 37: The GSK Strategic Collaboration

    Slide 37: The GSK Strategic Collaboration

    The GSK Strategic Collaboration Announced June 2014: Up-front payment £25 million GSK has option to license NY-ESO at end of Phase 1/2 studies Adaptimmune conducts all clinical and non-clinical development work Enables Adaptimmune to optimize regulatory, vector, cell processing, analytical, automati

  38. Slide 38: Large un-partnered pipeline with ability to target almost all major tumors

    Slide 38: Large un-partnered pipeline with ability to target almost all major tumors

    Large un-partnered pipeline with ability to target almost all major tumors Adaptimmune GSK 20+ Additional validated targets Twelve new targets selected for development Not yet nominated; programs with work ongoing are excluded Pool of 3: ADAP keeps 2 NY-ESO MAGE-A10 AFP 30+ validated therapeutic tar

  39. Slide 39: Key 2015/2016 Milestones YTD and Anticipated

    Slide 39: Key 2015/2016 Milestones YTD and Anticipated

    Key 2015/2016 Milestones YTD and Anticipated Q1 2015 Additions to Adaptimmune senior leadership team April 2015 AACR presented full cohort data for NY-ESO in Sarcoma and MM May 2015 IPO raises $176m net proceeds Q2 2015 Filing and acceptance of IND for Phase 1/2 studies for MAGE A-10 Q3 2015 Publica

  40. Slide 40: Investment Highlights

    Slide 40: Investment Highlights

    Investment Highlights Focused on affinity enhanced T-cell therapies for autologous T-cell therapeutics to treat cancer Lead clinical candidate targeting NY-ESO : SITC 2015 data Synovial sarcoma – In patients receiving target dose of 1x109 cells: 60% RR; 90% remain alive and on long-term follow up Mu

  41. Slide 41: Adaptimmune Engineered TCR T cell therapy

    Slide 41: Adaptimmune Engineered TCR T cell therapy

    Adaptimmune Engineered TCR T cell therapy Jefferies Autumn Global Healthcare Conference 18th November 2015

  42. Slide 42: Adaptimmune

    Slide 42: Adaptimmune

    Adaptimmune Engineered TCR T cell therapy Jefferies Autumn Global Healthcare Conference 18th November 2015 BY Adaptimmune

Source: SEC EDGAR · 6-K filed Nov 18, 2015

More decks from Adaptimmune Therapeutics PLC

All 10 Adaptimmune Therapeutics decks